Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
15 March 2022 - 7:05AM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced that
Jonathan Violin, Ph.D., President and Chief Executive Officer of
Viridian, will participate in a fireside chat at the 32nd Annual
Oppenheimer Healthcare Conference on March 15, 2022.
32nd
Annual Oppenheimer Healthcare Conference |
Format: |
|
Fireside Chat |
Date: |
|
Tuesday, March 15, 2022 |
Time: |
|
10:40 a.m. ET |
Webcast Link |
|
|
|
The live webcast and a replay of the fireside chat can be
accessed under “Events” in the Investors section of the Viridian
Therapeutics, Inc. website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jul 2023 to Jul 2024